Spine Disease Clinical Trial Representation: An Analysis of Racial, Ethnic, and Gender Diversity
These results indicate that racial and ethnic minorities in spine disease-related clinical trials remain under-represented relative to the US population even after the Revitalization Act of 1993, the Food and Drug Administration Amendments Act of 2007, Section 801, and the Final Rule policy. Furthermore, gender representation fluctuated after the enactment of the policies. For this reason, clinical trials should be more aware of having adequate representation during enrollment and more transparent in reporting race, ethnicity, and gender.
Authors
- Galal A. Elsayed (ORCID: https://orcid.org/0000-0002-5542-667X)
- Nikhil Dholaria (ORCID: https://orcid.org/0000-0002-0873-5525)
- Amna Hussein (ORCID: https://orcid.org/0000-0002-4694-9989)
- Yogendra Kumar Gupta (ORCID: https://orcid.org/0000-0002-8155-8158)
- Ali A. Baaj (ORCID: https://orcid.org/0000-0001-7487-0277)
- Giovanni Barbagli (ORCID: https://orcid.org/0000-0001-7297-788X)
- Vikas Agarwal (ORCID: https://orcid.org/0000-0002-7086-0239)
- Nitin Agarwal (ORCID: https://orcid.org/0000-0003-0256-3897)
- Daksh Singh
- Romir Parmar (ORCID: https://orcid.org/0009-0008-1378-2108)
- Sohail Daulat (ORCID: https://orcid.org/0009-0003-4751-6282)
Institutions
- NewYork–Presbyterian Hospital (US)
- University of Arizona (US)
- Cornell University (US)
- New York Hospital Queens (US)
- University of Pittsburgh Medical Center (US)
- Neurological Surgery (US)
Publication Details
- Journal
- Neurosurgery
- Published
- 2025-05-27
- DOI
- https://doi.org/10.1227/neu.0000000000003530
- Citations
- 1
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 3.13